diffuse large B‐cell lymphomaincidencepopulation outcomesrelative survival ratesurvivalPopulation‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data ...
弥漫大 B 细胞淋巴瘤(Diffuse large B cell lymphoma,DLBCL)是一种极具侵袭性且异质性很强的非霍奇金淋巴瘤,在全球范围内,其发病率较高,部分患者因癌基因的超突变而难以治愈。由于 DLBCL 的临床异质性明显,肿瘤微环境不断变化,30 - 40% 的患者对治疗无反应或会复发,这使得预后判断和治疗决策变得非常困难。目...
2025年4月,赵维莅教授、许彭鹏教授在《Cell Reports Medicine》【IF11.7,Q1】杂志发表题名为“Practical microenvironment classificationin diffuse large B cell lymphoma using digital pathology.”——基于数字病理学的弥漫性大B细胞淋巴瘤微...
通过评价无事件生存期（effect free survival, EFS）、无进展生存期（progression-free survival, PFS）、总生存期（overall survival, OS）、客观有效率（objective response rate, ORR），探寻ibrutinib联合R-CHOP化疗方案用于non-GCB DLBCL（主要为ABC DLBCL）的安全性及有效性【7】。数据显示，虽然ibrutinib的加入未...
是一组高度侵袭性的非霍奇金淋巴瘤,DHL/ THL绝大多数起源于生发中心B细胞(germinal center B-cell,GCB),临床进展快,预后差,利妥昔单抗联合长春新碱、阿霉素、环磷酰胺和泼尼松(R-CHOP)方案治疗DHL/THL疗效不佳,最佳客观缓解率(objective response rate,ORR)约为40%～...
B-cell lymphomas come in many types. Some grow quickly and others grow slowly. Your doctor will explain which type you have and how to treat it. Large B-cell lymphoma The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people wi...
B-cell lymphomais a common subtype of non-Hodgkin lymphoma (NHL), which is the seventh-most prevalent cancer in the United States and has the sixth-highestmortality rate[1]. The most frequently diagnosed B-cell lymphoma subtypes include diffuse large B-cell lymphoma (DLBCL; 31% of diagnosed...
弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)在中国是血液科发病率首位的非霍奇金淋巴瘤,其新发比例及肿瘤负担都较重。自上世纪抗CD20单抗面世以来,非霍奇金淋巴瘤这类淋巴造血系统疾病研究在近二十年突飞猛进,尤其是高度异质性的DLBCL。可喜的是50-60%患者可通过标准免疫化疗获得治愈,但有些高危因...
约70%的弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)患者经一线治疗可治愈,其余30%~40%患者并不能通过R-CHOP(利妥昔单抗+环磷酰胺+长春新碱+阿霉素+泼尼松)治愈,判断这类患者是否为高风险以及该如何识别这些患者从而进行提前干预是当前探索的热点。
①效应性B细胞(effector B cell,Beff)可产生自身抗体,如类风湿因子(rheumatoid factor,RF)和抗瓜氨酸蛋白抗体(anti-citrulline protein antibody,ACPA)等,这些抗体形成免疫复合物,沉积在关节中,并通过补体和细胞激活促进炎症过程;②B细胞作为有效的抗原提呈细胞(antigen presenting cell,APC),通过共刺激分子的表达激活...